Fortress Biotech Q1 net income $108.4M; PRV sale for $205M and ZYCUBO approval drive results

Fortress Biotech, Inc.

Net income $108.4M ($3.44 basic EPS) vs net loss $12.7M in Q1 2025; revenue $16.0M up from $13.1M.
Subsidiary Cyprium sold Rare Pediatric Disease PRV for $205M in March 2026; ZYCUBO approved for Menkes disease.
Debt reduced: prepaid Oaktree loan to $15M outstanding; cash increased to $255.8M from $79.4M.
Checkpoint acquisition by Sun Pharma gives Fortress ~$28M upfront + 2.5% royalty on UNLOXCYT sales.
Journey Medical's Emrosi launched; payer access expanded to 85% of US commercial lives.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fortress Biotech, Inc. reported the first quarter ended March 31, 2026 results: net income $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted).

Period: the first quarter ended March 31, 2026
Net income: $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)
Result: reported results

Exact text from the filing

Fortress’ consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted)

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-061208

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.